ICML 2025 | A Phase II study of ibrutinib and R-CHOEP in younger, high-risk patients with DLBCL

So we all know that young patients with high-risk DLBCL, H-adjusted IPI 2 to 3, they are challenging to treat and here we present the study of the German Lymphoma Alliance designed prior to the introduction of bispecific antibodies and novel antibody drug conjugates. So this study aimed to improve the results of conventional immunochemotherapy by adding of ibrutinib in standard doses to eight cycles of R-CHOEP. The primary endpoint of the study was progression-free survival and we compared the results with the historical cohort of the MEGA CHOEP study which had the same inclusion criteria. So we enrolled 40 patients in nine German centers. With a median follow-up of 31 months; the two-year progression-free survival was 83%, which was 8% better than the historical cohort from MEGA CHOEP studies with 130 patients with large B-cell lymphoma. Particularly, patients from the combination group received significantly less chemotherapy. Eight cycles of R-CHOEP were applied to 64% of patients in comparison to 88% of patients from the historical group, and radiotherapy was administered also two-fold less. So we could achieve these results by applying less chemotherapy and radiotherapy for this high-risk patient group. In addition, we could confirm that the study was safe and no adverse aspects were documented.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.